Tigenix S.A.U. clinical trials
Acquired by Takeda, Jun 2018 · source ↗
The registry lists 11 studies whose lead sponsor is Tigenix S.A.U.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 19, 2024.
Before and after it joined Takeda
- First submitted before Tigenix S.A.U. became part of Takeda
- 11
- First submitted after Tigenix S.A.U. became part of Takeda
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Tigenix S.A.U.11 studies
Something wrong with this grouping? Tell us on the Takeda page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Takeda studies →
- Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)CompletedNCT03279081Phase 3
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Cx611-0204 SEPCELL StudyCompletedNCT03158727Phase 1/2
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's DiseaseCompletedNCT01541579Phase 3
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys BullosaCompletedNCT00987142Phase 2
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Intralymphatic eASC Administration in Healthy VolunteersCompletedNCT01743222Phase 1
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled TrialCompletedNCT01020825
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis PatientsCompletedNCT01663116Phase 1/2
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.CompletedNCT01372969Phase 1/2
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s DiseaseCompletedNCT00475410Phase 3
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's DiseaseTerminatedNCT01378390Phase 3
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda
- Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human VolunteersCompletedNCT02328612Phase 1
Sponsor listed in the registry: Tigenix S.A.U. · First submitted before Tigenix S.A.U. became part of Takeda